Sermorelin 5MG

Sermorelin 5MG

Original price was: $69.00.Current price is: $53.00.

Sermorelin is a GHRH analogue that stimulates growth hormone secretion. It may improve bone density, reduce scarring, and combat dementia effects.

44 in stock (can be backordered)

Product Usage: This product is designated as a "Novelty Peptide" and is intended solely for specialized applications in controlled settings. It is not intended for any specific biological, therapeutic, or diagnostic use. All information provided on this website is for informational and educational purposes only and should not be construed as guidance for any particular application or usage.

download

Sermorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH), specifically consisting of the first 29 amino acids of the naturally occurring 44-amino acid GHRH. It is designed to stimulate the pituitary gland to produce and release endogenous growth hormone (GH). Sermorelin has been used for diagnostic evaluation of pituitary function and for treating growth hormone deficiency in children. In recent years, it has gained attention as a potential therapy for age-related growth hormone decline in adults, offering a more physiological approach to growth hormone restoration compared to direct GH administration.

Sequence:Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2

Molecular Formula:C14H246N44O42S

Molecular Weight:3357.882 Da

CAS Number:86168-78-7

  1. Growth Hormone Stimulation: Studies have shown that sermorelin effectively stimulates GH release from the pituitary gland, with one study demonstrating that it almost doubled the 12-hour mean amount of GH released in healthy elderly men.
  2. Body Composition: Research has indicated improvements in lean body mass and skin thickness in both men and women after extended sermorelin treatment, although changes in total body weight and fat mass were not consistently observed.
  3. Muscle Function: Some studies have reported significant improvements in muscle strength and endurance tests following sermorelin administration.
  4. Cardiovascular Effects: A decrease in mean systolic blood pressure was observed as an effect of sermorelin treatment in one study.
  5. Safety Profile: Multiple non-clinical studies have revealed no evidence of genotoxicological or toxicological concerns regarding the safety of sermorelin after chronic application.

  1. Long-term Efficacy: Extended studies are needed to evaluate the long-term effects and safety profile of sermorelin in various patient populations, particularly in the context of anti-aging therapy.
  2. Comparative Studies: Further research comparing sermorelin to other growth hormone-related therapies, including direct GH administration, is warranted to establish its relative efficacy and safety.
  3. Optimal Dosing Regimens: Investigation into optimal delivery methods and dosing frequencies for different conditions could enhance the therapeutic potential of sermorelin.
  4. Combination Therapies: Exploring potential synergistic effects of sermorelin with other therapeutic agents could open new avenues for treatment in various medical fields.
  5. Expanded Applications: Research into sermorelin's potential benefits in conditions such as cardiovascular disease, cognitive decline, and tissue repair is needed to fully understand its therapeutic scope.

  1. Corpas, E., et al. (1993). "Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men." Journal of Clinical Endocrinology & Metabolism, 76(5), 1344-1348. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/8496328/
  2. Khorram, O., et al. (1997). "Effects of [norleucine27] growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women." Journal of Clinical Endocrinology & Metabolism, 82(11), 3590-3596. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/9360513/
  3. Vittone, J., et al. (1997). "Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men." Metabolism, 46(1), 89-96. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/9005976/
  4. Stier, H., et al. (2013). "Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans." Journal of Endocrinology and Metabolism, 3(1-2), 7-15. [Online].
    Available: https://jofem.org/index.php/jofem/article/view/157/194
  5. Walker, R.F., et al. (1994). "Growth hormone secretion in healthy elderly men: assessment by deconvolution analysis and approximate entropy algorithm." American Journal of Physiology, 267(1 Pt 1), E150-E157. [Online].
    Available:https://pubmed.ncbi.nlm.nih.gov/8048505/
  6. Villalobos, C., et al. (1997). "Somatostatin and GHRH: synthesis, receptors, and intracellular signaling." Trends in Endocrinology & Metabolism, 8(10), 390-397. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/18406829/
AOD9604 represents a promising avenue for various therapeutic and cosmetic applications, particularly in fat metabolism and tissue repair. As with all research peptides, it is important to use AOD9604 in controlled settings, and its potential benefits and risks require further scientific scrutiny before any clinical applications can be considered.